Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes.

[1]  Francesco M Marincola,et al.  Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.

[2]  B. Seliger,et al.  HLA class I antigen abnormalities and immune escape by malignant cells. , 2002, Seminars in cancer biology.

[3]  J. Weber.  Peptide Vaccines for Cancer , 2002, Cancer investigation.

[4]  B. Seliger,et al.  Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.

[5]  F. Marincola,et al.  Heterogeneity in expression of human leukocyte antigens and melanoma‐associated antigens in advanced melanoma , 2000, Journal of cellular physiology.

[6]  D. Hunt,et al.  Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens , 2000, Cancer Immunology, Immunotherapy.

[7]  J. Shabanowitz,et al.  The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. , 1998, Cancer research.

[8]  D. Hunt,et al.  Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. , 1996, Journal of immunology.

[9]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[10]  R. Henderson,et al.  Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.